Phase I/II trial of paclitaxeal and cisplatin in patients with recurrent ovarian cancer
Phase 1
Recruiting
- Conditions
- Patients with hypersensitivity reaction to carboplatin (ovarian cancer, fallopian tubal cancer, primary peritneal cancer)
- Registration Number
- JPRN-UMIN000015496
- Lead Sponsor
- SchooMedicine, Chiba university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have a history of hypersensitivity to paclitaxeal. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hypersensitivity reactions to cisplatin
- Secondary Outcome Measures
Name Time Method Adverse events Progression free survival response rate (disease control rate) overall survival tolerability patients QO